Vaughn Smider
Affiliations: | 2006- | Scripps Research Institute |
Google:
"Vaughn Smider"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Huang R, Warner Jenkins G, Kim Y, et al. (2023) The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America. 120: e2303455120 |
Pekar L, Klewinghaus D, Arras P, et al. (2021) Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity. Frontiers in Immunology. 12: 742418 |
Haakenson JK, Huang R, Smider VV. (2018) Diversity in the Cow Ultralong CDR H3 Antibody Repertoire. Frontiers in Immunology. 9: 1262 |
Stanfield RL, Haakenson J, Deiss TC, et al. (2018) The Unusual Genetics and Biochemistry of Bovine Immunoglobulins. Advances in Immunology. 137: 135-164 |
Deiss TC, Vadnais M, Wang F, et al. (2017) Immunogenetic factors driving formation of ultralong VH CDR3 in Bos taurus antibodies. Cellular & Molecular Immunology |
Sok D, Le KM, Vadnais M, et al. (2017) Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature |
Stanfield RL, Wilson IA, Smider VV. (2016) Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies. Science Immunology. 1: aaf7962 |
Stanfield RL, Wilson IA, Smider VV. (2016) Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies. Science Immunology. 1 |
Vadnais ML, Smider VV. (2016) Bos taurus ultralong CDR H3 antibodies. Current Opinion in Structural Biology. 38: 62-67 |
Wold ED, Smider VV, Felding BH. (2016) Antibody Therapeutics in Oncology. Immunotherapy (Los Angeles, Calif.). 2 |